id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-D-0610-0010,FDA,FDA-2008-D-0610,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Draft Guidance for Industry on Postmarketing Adverse Event Reporting for Medical Products, etc.",Notice,General Notice,2011-06-24T04:00:00Z,2011,6,2011-06-24T04:00:00Z,2011-07-26T03:59:59Z,2011-06-24T18:53:04Z,2011-15799,0,0,0900006480eb3446
FDA-2008-D-0610-0009,FDA,FDA-2008-D-0610,Guidance for Industry Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic,Other,GDL-Guidance (Supporting and Related Materials),2011-01-10T05:00:00Z,2011,1,2011-01-10T05:00:00Z,2011-03-09T04:59:59Z,2020-03-19T19:31:38Z,,0,0,0900006480bc6e66
FDA-2008-D-0610-0008,FDA,FDA-2008-D-0610,Draft Guidance for Industry; Availability Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic,Notice,NAD-Notice of Availability of Data,2011-01-07T05:00:00Z,2011,1,2011-01-07T05:00:00Z,2011-03-09T04:59:59Z,2011-03-03T20:47:47Z,2011-00094,0,0,0900006480bc6d37